相关临床试验
221
70 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
19
8.6%
已完成
76
34.4%
尚未招募
51
23.1%
招募中
62
28.1%
暂停
1
0.5%
终止
7
3.2%
撤回
5
2.3%
暂无批准数据
- A phase 3 randomized clinical trial of 339 patients found that mirtazapine 30 mg daily reduced methamphetamine use by an average of 7 days compared to 4.8 days with placebo over 12 weeks. - The study represents the first large-scale trial of a readily available antidepressant for methamphetamine use disorder, addressing a critical unmet need with no approved medications worldwide. - While the treatment effect was modest (2.2 fewer use days), mirtazapine offers a safe, affordable option that could be prescribed off-label by physicians familiar with its use in depression. - Common side effects included drowsiness (47% vs 33%) and weight gain (10% vs 3%), with 23% discontinuing due to adverse events compared to 15% on placebo.
- Algorae Pharmaceuticals achieved independent preclinical validation of its AlgoraeOS v1 platform through testing 21 AI-predicted drug combinations across four cancer cell models at Peter MacCallum Cancer Centre. - The company's upgraded AlgoraeOS v2 platform identified 90 high-quality cannabidiol drug-combination candidates from analysis of over 500,000 potential combinations across 170 cell lines. - AlgoraeOS v2 demonstrated superior performance compared to state-of-the-art models including those from Google DeepMind across all major synergy prediction metrics. - The validation study confirmed AlgoraeOS can effectively prioritize drug combinations more likely to demonstrate real biological synergy, marking a critical technical de-risking milestone for AI-driven pharmaceutical development.
- A Cleveland Clinic study of over 1,000 patients found that low-dose ketamine infusions led to significant improvements in pain, physical function, and sleep for 20-46% of chronic pain patients, with benefits lasting at least six months. - A comprehensive Cochrane review analyzing 67 trials with 2,309 participants found no convincing evidence that ketamine provides meaningful benefits for chronic pain management compared to placebo. - The Cochrane review highlighted safety concerns including psychotomimetic effects such as delusions, delirium, and paranoia, while the Cleveland Clinic study reported minimal side effects with rare hallucinations. - Despite widespread off-label prescribing for chronic pain conditions, researchers emphasize the urgent need for high-quality trials to establish ketamine's true clinical value in pain management.
- Researchers identified suppression of the JNK signaling pathway, particularly through loss of MAP2K7, as a central mechanism driving resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. - CRISPR/Cas9 knockout screens revealed that MAP2K7 loss disrupts JNK activation and AP-1 transcription factor function, allowing cancer cells to evade stress responses like senescence and apoptosis while maintaining proliferation. - Tumor analysis showed that patients with low JNK pathway activity had poorer prognosis and reduced response to standard therapy, with higher risk of relapse during or after treatment. - The findings suggest JNK pathway assessment could serve as a biomarker for patient stratification, helping clinicians identify patients unlikely to respond to current treatment regimens.
- Researchers from the University of New South Wales developed PainWaive, an interactive brain training system that teaches patients to alter their brainwaves through neurofeedback games for nerve pain management. - In the first clinical trial, three out of four participants with corneal neuropathic pain experienced significant pain reductions five weeks after completing 20 treatment sessions over four weeks. - The system combines an EEG headset that records brain activity with an app featuring neurofeedback games, offering a potential non-invasive, in-home alternative to opioid treatments. - The promising results could lead to a new generation of drug-free treatments for chronic nerve pain conditions that rarely respond to current therapies.
- A new study suggests that triethylenetetramine (TETA), known as Cuprior, can improve outcomes for children with high-risk neuroblastoma. - Cuprior weakens tumors by transferring copper to immune cells and boosts the immune system's ability to fight the disease. - Researchers suggest Cuprior could improve current immunotherapy results, potentially increasing survival rates from 10 to 50 percent. - Repurposing existing drugs like Cuprior saves time and money compared to developing new treatments, offering a non-toxic option with minimal side effects.
